Precision Cancer Therapy in Rare Cancers

Sponsor
Oslo University Hospital
Study ID
NCT06119789
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Rare Malignant Neoplasm

Eligibility Criteria

Sex
ALL
Age
16 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Imatinib — DRUG
    imatinib treatment based on molecular alterations
  • Trametinib — DRUG
    According to biomarkers
  • Dabrafenib — DRUG
    According to biomarkers

Study Details

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Key Dates

Start date
Mar 20, 2025
Status verified
Mar 2025
Primary completion
Nov 30, 2033
Completion
Aug 1, 2036

Study Design

Enrollment
96 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment according to genetic alterations
    treatment according to genetic alterations

Primary Outcome Measure

Radiological response evaluation at 16 weeks of treatment [ Time Frame: 16 weeks ]

Central Contacts